Headache and Craniofacial Pain Unit, Neurology Department, Hospital Universitari Vall d'Hebron.
Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Curr Opin Neurol. 2019 Jun;32(3):395-404. doi: 10.1097/WCO.0000000000000689.
Migraine is a prevalent and extremely disabling brain disorder, with an impact on the individual, family, workplace and society. This review focuses on describing Calcitonin Gene Related Peptide Monoclonal Antibodies (CGRP-mABs) efficacy on improving the quality of life (QoL) and decreasing the disability and impact of migraine measured with patient related outcomes (PROs), on patients who participated in clinical trials with erenumab, fremanezumab, galcanezumab and eptinezumab. The goal is to better reflect the effect of these preventive migraine treatments in the daily life of our patients.
CGRP-mABs have been approved by the Food and Drug Administration's (FDA) and European Medicines Agency (EMA) as the first migraine specific treatment for the prevention of migraine. In clinical trials, CGRP-mABs have proven to achieve their primary endpoint which is to reduce the number of headache days, and also have shown to have an impact on disability, QoL and workplace productivity.
CGRP-mABs have an impact on the disability, QoL, workplace productivity and global impression of improvement of migraine, which will translate into changes in the real world of migraine patients who are treated with CGRP-mABs.
综述目的：偏头痛是一种常见且极具致残性的脑部疾病，对个人、家庭、工作场所和社会都会产生影响。本综述重点描述降钙素基因相关肽单克隆抗体（CGRP-mAB）在改善生活质量（QoL）和减少偏头痛致残和影响方面的疗效，这些疗效是通过患者相关结局（PROs）来衡量的，研究对象为接受依那西普单抗、弗里美昔单抗、加兰他敏和eptinezumab 临床试验的偏头痛患者。其目的是更好地反映这些预防性偏头痛治疗方法在我们患者日常生活中的效果。
最新发现：降钙素基因相关肽单克隆抗体已被美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）批准为偏头痛预防的首个偏头痛特异性治疗药物。临床试验证明，CGRP-mABs 不仅达到了减少头痛天数的主要终点，而且还对残疾、QoL 和工作场所生产力产生了影响。
总结：CGRP-mABs 对偏头痛的残疾、QoL、工作场所生产力和整体改善印象产生影响，这将转化为接受 CGRP-mABs 治疗的偏头痛患者的现实世界中的变化。
